Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Evotec AG (EVO), Legend Biotech (LEGN) and Inogen (INGN)

Tipranks - Tipranks - Thu Apr 16, 5:26AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evotec AG (EVO), Legend Biotech (LEGN) and Inogen (INGN) with bullish sentiments.

Claim 30% Off TipRanks

Evotec AG (EVO)

H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage with a Buy rating on Evotec AG today and set a price target of $7.00. The company’s shares closed last Tuesday at $3.12, close to its 52-week low of $2.85.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 15.5% and a 42.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Actuate Therapeutics, Inc., Unicycive Therapeutics, and Janux Therapeutics Inc. ;'>

Evotec AG has an analyst consensus of Moderate Buy, with a price target consensus of $4.67.

See Insiders’ Hot Stocks on TipRanks >>

Legend Biotech (LEGN)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Legend Biotech today and set a price target of $50.00. The company’s shares closed last Tuesday at $18.69.

According to TipRanks.com, Kapoor is a 4-star analyst with an average return of 9.9% and a 40.6% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Kyverna Therapeutics, Inc., BioMarin Pharmaceutical, and Crispr Therapeutics AG. ;'>

Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $54.71, representing a 206.5% upside. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $62.00 price target.

Inogen (INGN)

In a report released today, Michael Matson from Needham maintained a Buy rating on Inogen, with a price target of $12.00. The company’s shares closed last Tuesday at $6.34, close to its 52-week low of $6.14.

According to TipRanks.com, Matson is a 1-star analyst with an average return of -1.5% and a 40.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Establishment Labs Holdings, and Zimmer Biomet Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inogen with a $12.67 average price target, representing a 95.2% upside. In a report issued on April 7, Freedom Capital Markets also initiated coverage with a Buy rating on the stock with a $12.00 price target.

Read More on EVO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).